This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.

How to use FLUIDASA 5 mg/ml ORAL SOLUTION

Introduction

PACKAGE LEAFLET: INFORMATION FOR THE USER

FLUIDASA 5 mg/ml oral solution

Mepifilina (mepiramine acefyllinate)

Read all of this leaflet carefully before you start taking this medicine.

Keep this leaflet, you may need to read it again.
If you have any further questions, ask your doctor or pharmacist.
This medicine has been prescribed for you, do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
If you experience any of the side effects, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

Contents of the pack:

What Fluidasa Solution is and what it is used for
Before taking Fluidasa Solution
How to take Fluidasa Solution
Possible side effects
Storage of Fluidasa Solution
Further information

1. What FLUIDASA SOLUTION is and what it is used for

This medicinal product contains mepifilina, which belongs to the group of antihistamine medicines.

Fluidasa Solution is used for the treatment of bronchoconstriction in patients with acute and chronic bronchitis (inflammation of the bronchi).

2. Before taking FLUIDASA SOLUTION

Do not take Fluidasa Solution:

If you are allergic (hypersensitive) to mepifilina or any of the other ingredients of Fluidasa Solution.
If you have any liver disease.
If you have urinary bladder obstruction.
If you have symptomatic prostatic hypertrophy or urinary retention.
If you have narrow-angle glaucoma.
If you have fructose intolerance because this medicinal product contains a sugar called sorbitol.

Be cautious when taking Fluidasa Solution:

If you are sensitive to antihistamines (allergy medicines) as patients sensitive to one antihistamine may be sensitive to others.
If you are an elderly patient as you are more likely to experience side effects such as dizziness, sedation, confusion, low blood pressure, dry mouth, or urinary retention. If these effects persist or are severe, you should inform your doctor in case the medication needs to be discontinued.
It is not recommended for use in newborns or premature infants due to the increased sensitivity to some effects of the medicinal product, such as anticholinergic effects (e.g., central nervous system stimulation) and a greater tendency to convulsions.

Use of other medicines:

Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including those obtained without a prescription.

Especially, inform your doctor if you are taking the following medicines as some of their effects may be increased:

Medicines belonging to the group of anticholinergic medicines (e.g., some medicines used for relief of spasms or contractions of the stomach, intestine, or bladder)
Medicines used for the treatment of depression, such as monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, or maprotiline.
If skin allergy tests need to be performed, it is recommended to discontinue the administration of Fluidasa Solution at least 72 hours before starting the test as it may give false-negative results (negative results that are actually positive).

Taking Fluidasa Solution with food and drinks:

You should avoid consuming alcoholic beverages during the administration of this medicinal product as it may increase the effects of alcohol.

Pregnancy and breastfeeding

It is not recommended to take Fluidasa Solution during pregnancy.

It is not recommended to take Fluidasa Solution during breastfeeding.

Consult your doctor or pharmacist before using any medicine.

Driving and using machines:

Fluidasa Solution may cause drowsiness, affecting mental and/or physical ability. If you experience these effects, avoid driving vehicles or using machines.

Important information about some of the ingredients of Fluidasa Solution

This medicinal product contains sorbitol. If your doctor has told you that you have an intolerance to some sugars, consult with them before taking this medicinal product. It may have a mild laxative effect as it contains 4 g of sorbitol per 15 ml dose.

Caloric value: 2.6 kcal/g of sorbitol.

It may cause allergic reactions (possibly delayed) as it contains methyl parahydroxybenzoate (E-218) and propyl parahydroxybenzoate (E-216).

3. How to take FLUIDASA SOLUTION

Fluidasa Solution is administered orally.

Follow exactly the administration instructions of Fluidasa Solution as indicated by your doctor.

Consult your doctor or pharmacist if you have any doubts.

1 dose of 5 ml contains approximately 25 mg of mepifilina, and 1 dose of 15 ml contains 75 mg of mepifilina.

The average normal dose is 8 mg per kg of body weight and day, divided into 4 doses. The maximum dose is 18 mg per kg of body weight and day, divided into 4 doses.

The normal dose, as a guideline and in relation to body weight, is as follows:

Children under 5 years: 5 to 10 ml of the solution, 3 or 4 times a day.
Children over 5 years: 10 to 15 ml of the solution, 3 or 4 times a day.
Adults: 15 to 30 ml (one or two 15 ml doses) of the solution, 4 times a day.

Instructions for correct administration

Take the amount of medicine to be taken using the measuring cup that has the following measures marked: 2.5 ml, 5 ml, 7.5 ml, 10 ml, and 15 ml. Fill it with the solution up to the line indicating your dose. After use, wash the measuring cup with water.

Transparent syringe with measurement marks in milliliters indicating 2.5ml, 5ml, 7.5ml, 10ml, and 15ml

In infants, it is recommended to use Fluidasa Drops.

If you feel that the effect of Fluidasa Solution is too strong or too weak, consult your doctor or pharmacist.

If you take more Fluidasa Solution than you should:

If you have taken more Fluidasa Solution than you should, consult your doctor or pharmacist immediately.

In cases of overdose, symptoms of anticholinergic effects such as clumsiness, instability, intense sleep, dry mouth, nose, or throat, flushing, or redness, variations in the normal heart rate, central nervous system depression (hallucinations), or low blood pressure may appear. In children, anticholinergic stimulant effects on the CNS are more likely.

In case of overdose or accidental ingestion, consult the Toxicology Information Service, phone: 91 562 04 20.

If you forget to take Fluidasa Solution:

Do not take a double dose to make up for forgotten doses.

Take your dose as soon as possible and continue taking it every day at the time indicated by your doctor.

4. Possible side effects

Like all medicines, Fluidasa Solution can cause side effects, although not everybody gets them.

The side effects found have been:

Very common (at least 1 in 10 patients): drowsiness.

Common (at least 1 in 100 patients): blurred vision, confusion, difficulty urinating, dizziness, dry mouth, rapid heart rate, ringing in the ears, skin rash, discomfort or pain in the stomach.

Uncommon (at least 1 in 1000 patients): abnormal blood conditions (blood dyscrasias) and variations in the normal heart rate.

If you experience any side effect that you think is serious or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

Reporting of side effects

If you experience any side effects, consult your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report them directly through the Spanish Medicines and Health Products Agency's website: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicinal product.

5. Storage of FLUIDASA SOLUTION

Keep out of the reach and sight of children.

Do not store above 25°C.

Do not use Fluidasa solution after the expiry date stated on the packaging after CAD. The expiry date is the last day of the month indicated.

Medicines should not be disposed of via wastewater or household waste. Place the packaging and any unused medicines in the SIGRE collection point at your pharmacy. If you have any further questions, ask your pharmacist how to dispose of the packaging and any unused medicines. This will help protect the environment.

6. Further information

Composition of Fluidasa solution

The active ingredient is: mepifilina (mepiramine acefyllinate). Each ml of solution contains 5 mg of mepifilina.
The other ingredients are: sodium saccharin, sorbitol (E-420), methyl parahydroxybenzoate (E-218), propyl parahydroxybenzoate (E-216), vanilla flavor, and purified water.

Appearance and packaging of the product

Topaz glass bottle containing 250 ml of oral solution accompanied by a 15 ml measuring cup

Marketing authorization holder and manufacturer:

Marketing authorization holder:

Teofarma, S.r.l.

Via F. Lli Cervi, 8

27010 Valle Salimbene (PV) – Italy

Manufacturer:

Teofarma S.r.l.

Viale Certosa, 8/A

27100 Pavia – Italy

Other presentations

Fluidasa Drops. Bottle of 30 ml oral solution and dropper cap.

Fluidasa Capsules. Package of 20 capsules.

Fluidasa Injectable. Package containing 10 ampoules of 5 ml.

This leaflet was approved in July 2022

Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/

How much does FLUIDASA 5 mg/ml ORAL SOLUTION cost in Spain ( 2026)?

The average price of FLUIDASA 5 mg/ml ORAL SOLUTION in January, 2026 is around 4.21 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.

Dr. Muhammad Tayyab Altaf is a primary care physician with extensive international experience, offering online consultations for adults and children. His background includes clinical practice in Italy, the United States and other healthcare settings, allowing him to manage a wide range of acute and chronic medical conditions with confidence and clarity.

His clinical expertise spans multi-system conditions, preventive care and long-term management of chronic diseases. Dr. Altaf combines hands-on experience with a strong research background in both medical and surgical fields, enabling him to provide accurate assessments and structured, evidence-based treatment plans. Patients value his ability to explain diagnoses clearly, outline next steps and support them in making informed healthcare decisions.

Online consultations with Dr. Altaf are suitable for many everyday and acute situations where a timely medical opinion can help determine the safest next steps. He evaluates and treats conditions affecting the cardiovascular, respiratory, gastrointestinal, neurological, haematological and endocrine systems. Common examples include:

hypertension and other blood pressure issues
ischaemic heart disease and angina
asthma, COPD and emphysema
pneumonia and lung fibrosis
gastroenteritis and digestive infections
liver conditions, including alcohol-related disease
epilepsy, seizures and post-stroke symptoms
dementia and cognitive decline
anaemia and other haematological changes
diabetes, thyroid disorders and pituitary disease

Many patients reach out when they experience new or worsening symptoms, fluctuations in blood pressure, non-severe chest discomfort, breathing symptoms, digestive issues, suspected infections, chronic fatigue or concerns that affect daily life. He also helps patients understand test results, adjust existing treatment plans and navigate long-term health strategies safely and effectively.

When clinically appropriate, Dr. Altaf can also provide health and fitness certificates, including documentation required for physical activity, sports participation or gym use, based on the patient’s health status and medical indications.

Some conditions are not suitable for online care. Severe chest pain, loss of consciousness, uncontrolled bleeding, seizures, major trauma or symptoms suggesting a stroke or heart attack require immediate attention from local emergency services. Dr. Altaf prioritises patient safety and will guide you accordingly if your situation needs urgent in-person care.

In all consultations, Dr. Muhammad Tayyab Altaf focuses on clear communication, accurate diagnosis and patient-centred decision-making. His approach ensures that individuals and families feel informed, supported and confident in their next steps, no matter where they are.

FLUIDASA 5 mg/ml ORAL SOLUTION

Oksana Khlopushyna

Tarek Agami

Oksana Khlopushyna

Tarek Agami